Explore a selection of our essential drug information below, or:
Identification
- Summary
Calcium polycarbophil is a bulk forming laxative used to treat constipation.
- Brand Names
- Fiber Tab, Fibercon
- Generic Name
- Calcium polycarbophil
- DrugBank Accession Number
- DB14684
- Background
Calcium polycarbophil is a stool stabilizer. Based on its chemical structure, it is a synthetic polymer of polyacrylic acid cross-linked with divinyl glycol presenting a calcium atom as a counter-ion. Polycarbophil is used to treat constipation. This drug may also be used to help relieve the symptoms of irritable bowel syndrome or diarrhea.
Less gas and bloating compared to psyllium laxative products, but can cause heartburn, and belly cramps. It is insoluble in water, dilute acids, and dilute alkali. The material possesses exceptionally high water-binding capacity. is not absorbed, does not interfere with the activity of digestive enzymes or intestinal absorption, possesses satisfactory stability, is physiologically inert, and does not cause gastrointestinal irritation.
- Type
- Small Molecule
- Groups
- Approved
- Synonyms
- Calcium polycarbophil
- Polycarbophil calcium
- Polycarbophil, calcium
Pharmacology
- Indication
Polycarbophil is used to treat constipation and to help maintain regular bowel movements.
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
Indication Type Indication Combined Product Details Approval Level Age Group Patient Characteristics Dose Form Treatment of Constipation ••• ••• •••••••• •••••• - Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Relieves constipation or diarrhea associated with bowel disorders and acute nonspecific diarrhea.
- Mechanism of action
It is known as a bulk-forming laxative. It increases the bulk in the stool, an effect that helps to cause movement of the intestines. It also works by increasing the amount of water in the stool, making the stool softer and easier to pass.
- Absorption
Calcium polycarbophil is not absorbed from the intestine.
- Volume of distribution
Calcium polycarbophil is not absorbed from the intestine.
- Protein binding
Calcium polycarbophil is not absorbed from the intestine.
- Metabolism
Polycarrbophil calcium is not metabolized and has limited hydrophilic activity in acidic environments.
- Route of elimination
Excreted in feces.
- Half-life
Calcium polycarbophil is not absorbed from the intestine.
- Clearance
Calcium polycarbophil is not absorbed from the intestine.
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
The LD50 of calcium polycarbophil in young adult rats approximated 20 g/kg.
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAcebutolol The therapeutic efficacy of Acebutolol can be decreased when used in combination with Calcium polycarbophil. Acetazolamide The risk or severity of dehydration can be increased when Acetazolamide is combined with Calcium polycarbophil. Acetyldigitoxin Calcium polycarbophil may increase the arrhythmogenic and cardiotoxic activities of Acetyldigitoxin. Aclidinium The therapeutic efficacy of Calcium polycarbophil can be decreased when used in combination with Aclidinium. Alendronic acid The serum concentration of Alendronic acid can be decreased when it is combined with Calcium polycarbophil. - Food Interactions
- Take with a full glass of water.
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Active Moieties
Name Kind UNII CAS InChI Key Calcium salt SY7Q814VUP 7440-70-2 OYPRJOBELJOOCE-UHFFFAOYSA-N Polycarbophil salt W25LM17A4W 9003-97-8 Not applicable - Over the Counter Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Best Choice Tablet, film coated 625 mg/1 Oral Best Choice (Valu Merchandisers Company) 2019-04-16 Not applicable US 
Calcium Polycarbophil Tablet, film coated 625 mg/1 Oral CVS Pharmacy, Inc 2021-05-17 Not applicable US Calcium Polycarbophil Tablet, film coated 625 mg/1 Oral Cardinal Health 2020-11-18 Not applicable US Calcium Polycarbophil Tablet, film coated 625 mg/1 Oral Shandong Xinhua Pharmaceutical Co., Ltd. 2023-04-12 Not applicable US Calcium Polycarbophil 625 mg Tablet 625 mg/1 Oral REMEDYREPACK INC. 2016-10-10 2018-09-05 US
Categories
- ATC Codes
- A06AC08 — Polycarbophil calcium
- Drug Categories
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 8F049NKY49
- CAS number
- 126040-58-2
References
- General References
- External Links
- Wikipedia
- Polycarbophil_calcium
Clinical Trials
- Clinical Trials
Clinical Trial & Rare Diseases Add-on Data Package
Explore 4,000+ rare diseases, orphan drugs & condition pairs, clinical trial why stopped data, & more. Preview package Phase Status Purpose Conditions Count Start Date Why Stopped 100+ additional columns Unlock 175K+ rows when you subscribe.View sample dataNot Available Completed Treatment Type 2 Diabetes Mellitus 1 somestatus stop reason just information to hide 3 Not Yet Recruiting Treatment Brain Metastases / Human Epidermal Growth Factor 2 Negative Carcinoma of Breast / Metastatic Malignant Neoplasm to the Leptomeninges 1 somestatus stop reason just information to hide
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Tablet Oral 625 mg Tablet Oral 500 mg/1 Tablet, film coated Oral 625 mg/1 Tablet Oral 625 mg/1 Capsule Oral 625 mg/1 Tablet Oral 500 mg - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
- Not Available
- Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Not Available
- Chromatographic Properties
Collision Cross Sections (CCS)
Not Available
Drug created at September 06, 2018 02:00 / Updated at October 05, 2024 03:14